NCT06640361View on ClinicalTrials.gov

A Study of Olverembatinib in SDH-deficient GIST.

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2029

Conditions
GIST
Interventions
DRUG

Olverembatinib

Oral administration with meal, QOD, every 28 days for a cycle.

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
collaborator

HealthQuest Pharma Inc.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT06640361 - A Study of Olverembatinib in SDH-deficient GIST. | Biotech Hunter | Biotech Hunter